A Phase I Clinical Study to Determine the Optimal Dose for the Safe Immune Restoration and Immune Response of Allogeneic Cell Immunotherapy (ACIT-1) in Adult Cancer Patients
Latest Information Update: 29 Feb 2024
At a glance
- Drugs ACIT 1 (Primary)
- Indications Cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Cancer Vaccines Limited
- 23 Feb 2024 Planned End Date changed from 1 Feb 2025 to 1 Feb 2026.
- 23 Feb 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Apr 2025.
- 24 Feb 2023 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.